🚀 Meta ends third-party fact checking

In partnership with

Could this be the biggest disruption to Smartphones in the past 15 years? 📲

💥Heads up! There's a new disruptor in smartphones: Mode Mobile. Mode can turn your phone from a cost into an income source — and investors are watching the launch of the company’s pre-IPO offering.¹

🤳Mode saw 32,481% revenue growth from 2019 to 2022, ranking them the #1 overall software company on Deloitte’s most recent fastest-growing companies list. Mode’s flagship product EarnPhone, a budget smartphone, has already helped consumers earn & save $325M+.

🫴 Mode’s Pre-IPO offering¹ is live at $0.25/share — 20,000+ shareholders already participated in its previous sold-out offering. There’s still time to get in on Mode’s pre-IPO raise and even lock in 100% bonus shares² … but only until their current raise closes for good.

Claim this exclusive bonus while you can!³

¹ Mode Mobile currently has no formal plans for an IPO.
² A minimum investment of $1,950 is required to receive bonus shares. 100% bonus shares are offered on investments of $9,950+.
³ Please read the offering circular and related risks at invest.modemobile.com. This is a paid advertisement for Mode Mobile’s Regulation A+ Offering.
Past performance is no guarantee of future results. Start-up investments are speculative and involve a high degree of risk. Those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investment tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Further, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns.
DealMaker Securities LLC, a registered broker-dealer, and member of FINRA | SIPC, located at 105 Maxess Road, Suite 124, Melville, NY 11747, is the Intermediary for this offering and is not an affiliate of or connected with the Issuer. Please check our background on FINRA's BrokerCheck.

Market Overview
Read time 1.4 minutes

Year To Date Performances:

1. Meta announced the end of its third-party fact-checking program, replacing it with a "Community Notes" system modeled after Musk’s platform X, as part of a broader push to restore "free expression" and align with President-elect Trump. CEO Mark Zuckerberg cited public trust erosion and political bias in fact-checking as key issues, alongside plans to simplify content policies and relocate trust and safety teams to Texas. The move signals Meta’s effort to rebuild its relationship with conservative leaders and Trump, whose accounts were reinstated earlier this year. Critics, including FTC Chair Lina Khan, voiced concerns over Meta’s unchecked influence on online speech.

2. FTC Chair Lina Khan expressed concerns about the potential for "sweetheart deals" that could let Amazon and Meta off the hook in pending antitrust lawsuits under the incoming Trump administration. Khan, a Biden appointee known for her tough stance on anticompetitive practices, highlighted ongoing cases against both companies and noted their efforts to court favor with President-elect Trump, including $1 million donations to his inauguration fund and high-profile visits to Mar-a-Lago. While Khan emphasized the FTC’s successes, she acknowledged uncertainty about how future leadership—under Trump’s pick, Andrew Ferguson—might handle these high-stakes cases.

3. Hims & Hers Health confirmed a $1 million donation to President-elect Donald Trump’s inauguration fund, joining other tech companies like OpenAI and Meta in aligning with the incoming administration. Known for its digital health innovations, the company gained significant traction last year with its weight loss program featuring compounded semaglutide, a cheaper alternative to brand-name drugs like Ozempic. The future of these treatments, however, remains uncertain as Trump's appointees hold varied opinions: Robert F. Kennedy Jr., tapped for HHS, advocates lifestyle changes over medication, while FDA pick Dr. Marty Makary and Trump ally Elon Musk have supported GLP-1 drugs for broader access. Hims & Hers has pledged to work with the administration to highlight the benefits of these treatments.

4. Headlines

   1. High treasury yields are putting pressure on the S&P500.

   2. Prices are falling in the UK housing market after sustained prices despite rising inventory over the last year.

   _{* This is sponsored content.}

Are you looking to grow your business? Here is how I can help: 

📱Book a Strategy Call to get 1:1 feedback on your pitch, pitch deck and/or fundraising strategy. (If you need general startup advice, then reply to this email, and I’ll let you know if/how I can help.)

Learn how to make AI work for you

AI won’t take your job, but a person using AI might. That’s why 800,000+ professionals read The Rundown AI – the free newsletter that keeps you updated on the latest AI news and teaches you how to use it in just 5 minutes a day.

Sign up to start learning.

Onwards and Upwards,

Liam Gill